Abstracts tagged "Cardiovascular disease and rheumatoid arthritis (RA)"

Abstract Number: 510 • 2018 ACR/ARHP Annual Meeting
Lipid Profile and Cardiovascular Risk in Subjects at Risk for Rheumatoid Arthritis
Laurette van Boheemen¹, Marian van Beers-Tas², Dirkjan van Schaardenburg³ and Michael Nurmohamed², ¹Rheumatology, Amsterdam Rheumatology and Immunology Center | Reade, Amsterdam, Netherlands, ²Amsterdam Rheumatology and Immunology Center | Reade, Amsterdam, Netherlands, ³Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune disease associated with an increased cardiovascular (CV) risk that is already present at the time of…
Abstract Number: 518 • 2018 ACR/ARHP Annual Meeting
Cardiometabolic Risk Factors Impact on the Cardioprotective Effect of Apelin on Systolic and Diastolic Function, in Patients with Rheumatoid Arthritis
Sulé Gunter¹, Lebogang Mokotedi², Monica Gomez², Linda Tsang², Aletta Millen³ and Patrick Dessein², ¹Depeartment of Health Sciences, School of Physiology, University of the Witwatersrand, Johannesburg, South Africa, ²Department of Health Sciences, School of Physiology, University of the Witwatersrand, Johannesburg, South Africa, ³Department of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: The rheumatoid arthritis (RA) population demonstrate a significantly increased incidence of cardiac events. Cardiac dysfunction in RA may occur as a result of impaired…
Abstract Number: 540 • 2018 ACR/ARHP Annual Meeting
Echocardiographic Abnormalities in Rheumatoid Arthritis Patients Compared to Age, Sex and Traditional Cardiovascular Risk Factors Matched Controls
Suad Hannawi¹, Kashif Naeem², Haifa Hannawi³ and Issa Al Salmi⁴, ¹Rheumatology Department. Ministry of Health and Prevention, Asst.Prof, Dubai, United Arab Emirates, ²Cardiology Department. Ministry of Health and Prevention, Dr, Dubai, United Arab Emirates, ³Research Department. Ministry of Health and Prevention, Asst.Prof, Dubai, United Arab Emirates, ⁴Prof, Muscat, Oman
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease of the joints with several extra-articular features. Cardiovascular disease (CVD) mortality accounts for 40-50% of…
Abstract Number: 1521 • 2018 ACR/ARHP Annual Meeting
Anti-IL-6 Therapy Modulates Leptin in Patients with Rheumatoid Arthritis
Sara Remuzgo-Martínez¹, Fernanda Genre¹, Verónica Pulito-Cueto¹, Verónica Mijares¹, Leticia Lera-Gómez¹, Jaime Calvo-Alén², Ricardo Blanco¹, Oreste Gualillo³, Javier Llorca⁴, Santos Castañeda⁵, Raquel Lopez-Mejías¹ and Miguel Angel González-Gay^1,6,7, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ²Rheumatology Department, Hospital Universitario Araba. Vitoria-Gasteiz, Alava, Spain, ³SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), The NEIRID Group (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Santiago University Clinical Hospital, Santiago de Compostela, Spain, Santiago de Compostela, Spain, ⁴Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, Santander, Spain, ⁵Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain, ⁶Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁷School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain
Background/Purpose: Leptin is an adipokine that plays an important role in the regulation of body weight and also participates in immune homeostasis and inflammatory processes1,2.…
Abstract Number: 2815 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Safety – Update from up to 6 Years of Treatment with Baricitinib in Rheumatoid Arthritis Clinical Trials
Michael Weinblatt¹, Peter C. Taylor², Gerd R. Burmester³, Chadi Saifan⁴, Chad D. Walls⁴, Maher Issa⁴, Terence P. Rooney⁴ and Tsutomu Takeuchi⁵, ¹Brigham and Women’s Hospital, Boston, MA, ²Botnar Research Centre, Univ of Oxford, Oxford, United Kingdom, ³Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Baricitinib (BARI), a selective inhibitor of Janus kinases, is approved in >40 countries for the treatment of active rheumatoid arthritis (RA) in adults. Patients…
Abstract Number: 2816 • 2018 ACR/ARHP Annual Meeting
Development of a Microrna Panel for Predicting Coronary Atherosclerosis in Rheumatoid Arthritis
Michelle J. Ormseth¹, Joseph F. Solus¹, Quanhu Sheng¹, Fei Ye¹, Yan Guo¹, Qiong Wu¹, Annette M. Oeser¹, Ryan Allen¹, Paolo Raggi², Kasey Vickers¹ and C Michael Stein¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of Alberta, Edmonton, AB, Canada
Background/Purpose: Small noncoding RNAs (sRNAs), such as microRNAs (miRNAs), regulate gene expression and can be used as biomarkers of disease. Patients with rheumatoid arthritis (RA)…
Abstract Number: 68 • 2018 ACR/ARHP Annual Meeting
A Genome-Wide Association Study Identifies rs116199914 As an Intergenic Variant Associated with Carotid Intima-Media Thickness in Spanish Patients with Rheumatoid Arthritis
Raquel Lopez-Mejías¹, Fernanda Genre¹, Sara Remuzgo-Martínez¹, David Carmona^2,3, Verónica Pulito-Cueto¹, Carlos González-Juanatey⁴, Alfonso Corrales¹, Esther Vicente⁵, Jose A. Miranda-Filloy⁶, Beatriz-Segura Tejera⁷, Marco A. Ramírez Huaranga⁸, Verónica Mijares¹, Leticia Lera-Gomez¹, Ricardo Blanco¹, Montserrat Robustillo-Villarino⁹, Javier Rodríguez-Carrio¹⁰, Ana Suárez¹⁰, Mercedes Alperi-López¹¹, Francisco Javier Ballina-García¹², Francisco Javier López Longo¹³, Francisco Javier Narváez¹⁴, Juan José Alegre⁹, Antonio Mera¹⁵, Eva Perez Pampín¹⁶, Antonio Gonzalez¹⁷, Enrique Raya Álvarez¹⁸, Chary López-Pedrera¹⁹, Carmen Gomez Vaquero¹⁴, Alejandro Balsa²⁰, Dora Pascual-Salcedo²⁰, Patricia Carreira²¹, Isidoro Gonzalez-Alvaro⁵, Luis Rodriguez Rodriguez²², Benjamin Fernandez Gutierrez²², Ivan Ferraz-Amaro²³, Santos Castañeda²⁴, Javier Martin³, Javier Llorca²⁵ and Miguel Angel González-Gay^1,26,27, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ²Departamento de Genética e Instituto de Biotecnología, Universidad de Granada, Granada, Spain, ³Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Granada, Spain, ⁴Division of Cardiology, Hospital Universitario Lucus Augusti, Lugo, Spain, ⁵Rheumatology Department, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ⁶Rheumatology Department, Hospital Universitario Lucus Augusti, Lugo, Spain, ⁷Rheumatology Division, Hospital Insular de Gran Canaria, Las Palmas, Spain, ⁸Rheumatology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, ⁹Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain, ¹⁰Area of Immunology, Department of Functional Biology, University of Oviedo, Oviedo, Spain, ¹¹Department of Rheumatology, Hospital Universitario Central de Asturias, Asturias, Spain, ¹²Department of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ¹³Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ¹⁴Rheumatology Department, Hospital Universitario de Bellvitge, Idibell, Barcelona, Spain, ¹⁵Rheumatology Division. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, ¹⁶Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, ¹⁷Laboratorio Investigacion 10 and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ¹⁸Rheumatology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ¹⁹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²⁰Rheumatology Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, ²¹Servicio de Reumatología, Hospital Universitario, Madrid, Spain, ²²Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain, ²³Rheumatology Division, Hospital Insular de Gran Canaria, La Laguna, Spain, ²⁴Rheumatology, Rheumatology Department, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ²⁵School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain, ²⁶School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain, ²⁷Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Cardiovascular (CV) disease is the most common cause of morbidity and mortality in patients with rheumatoid arthritis (RA) [1, 2]. Traditional CV risk factors…
Abstract Number: 85 • 2018 ACR/ARHP Annual Meeting
Antibodies to Citrullinated Protein Antigens (ACPAs) Induce Adipose Tissue Dysfunction Contributing to the Cardiovascular Disease Risk in Rheumatoid Arthritis. Modulation By Biological Dmards
Nuria Barbarroja¹, Ivan Arias de la Rosa², Miriam Ruiz-Ponce³, Maria Dolores de la Rosa-Garrido³, Patricia Ruiz-Limon⁴, Yolanda Jiménez-Gómez¹, Carlos Perez-Sanchez¹, Maria Carmen Abalos-Aguilera², Rocio Guzman-Ruiz⁵, Maria del Mar Malagon⁶, Francisco Jose Tinahones⁷, Eduardo Collantes-Estévez¹, Chary Lopez-Pedrera³ and Alejandro Escudero-Contreras², ¹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁴Research Group of Endocrine Diseases, Research Laboratory. Biomedical Research Institute of Malaga (IBIMA).Virgen de la Victoria Universitary Hospital, Malaga, Spain., Málaga, MA, Spain, ⁵Department of Cell Biology, Physiology, and Immunology,, IMIBIC/University of Córdoba/Reina Sofía University Hospital, Cordoba, Spain, ⁶Department of Cell Biology, Physiology, and Immunology,I, IMIBIC/University of Córdoba/Reina Sofía University Hospital, Cordoba, Spain, ⁷Department of Clinical Endocrinology and Nutrition, Institute of Biomedical Research of Málaga (IBIMA), Hospital of Málaga (Virgen de la Victoria), University of Málaga (UMA), Málaga, Spain; CIBER Fisiopatología Obesidad y Nutrición, Instituto de Salud Ca, Malaga, Spain
Background/Purpose: 1) To test the relationship among ACPAs and levels of adipocytokines and atherosclerosis in RA patients. 2) To analyze the effects of ACPAs on…
Abstract Number: 209 • 2018 ACR/ARHP Annual Meeting
Development of an Algorithm for the Classification of Cardiovascular Comorbidity in Rheumatoid Arthritis: Data from the Ontario Best Practices Research Initiative
Kangping Cui^1,2, Mohammad Movahedi³, Claire Bombardier⁴ and Bindee Kuriya⁵, ¹Internal Medicine, University of Western Ontario, London, ON, Canada, ²Toronto General Hospital Research Institute, Toronto, ON, Canada, ³JSS Medical Research, St-Laurent, QC, Canada, ⁴Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁵Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Development of an Algorithm for the Classification of Cardiovascular Comorbidity in Rheumatoid Arthritis: Data from the Ontario Best Practices Research InitiativeBackground/Purpose: Cardiovascular disease (CVD) is…
Abstract Number: 138 • 2017 ACR/ARHP Annual Meeting
Prediction of Cardiovascular Events in Rheumatoid Arthritis Patients Using a Multi-Biomarker of Disease Activity
Fenglong Xie¹, Lang Chen², Huifeng Yun² and Jeffrey R. Curtis³, ¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The ACC/AHA recommends preventive strategies for patients with a high predicted risk of atherosclerotic cardiovascular disease (CVD). RA patients are at higher risk for…
Abstract Number: 867 • 2017 ACR/ARHP Annual Meeting
Highly Sensitive Cardiac Troponin-I in Peripheral Blood Predicts Cardiovascular Events in Patients with Rheumatoid Arthritis
George Karpouzas¹, Joel Estis², Long Pham³, John Todd² and Matthew Budoff⁴, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Singulex, Alameda, California, Alameda, CA, ³Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ⁴Cardiology, Harbor-UCLA Medical Center, Torrance, CA
Background/Purpose: Cardiac troponins (cTn) are specific biomarkers of myocardial injury; their measurement with highly-sensitive assays and at subthreshold levels for myocardial infarction (MI) diagnosis, predicts…
Abstract Number: 869 • 2017 ACR/ARHP Annual Meeting
Utility of Carotid Ultrasound Compared to Framingham Risk Score in Predicting Cardiovascular Mortality in Rheumatoid Arthritis
Pankhuri Gupta¹, Agustin Escalante², Daniel F. Battafarano³, Jose Felix Restrepo² and Inmaculada del Rincon², ¹Rheumatology, University of Texas Health Science Center at San Antonio, SAN ANTONIO, TX, ²Internal Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ³Medicine, San Antonio Military Medical Center, San Antonio, TX
Background/Purpose: Rheumatoid arthritis (RA) patients have a greater risk of cardiovascular (CV) mortality compared to general population. Traditional CV risk factors may be less accurate…
Abstract Number: 872 • 2017 ACR/ARHP Annual Meeting
Myocardial Abnormalities Improve in RA Patients Treated Actively – a Cardiac MRI Follow-up Study
Riitta Koivuniemi^1,2, Mia Holmström³, Antti Kuuliala², Sari Kivistö³ and Marjatta Leirisalo-Repo^1,2, ¹Rheumatology, University of Helsinki, Helsinki, Finland, ²Rheumatology, Helsinki University Hospital, Helsinki, Finland, ³Radiology, HUS Medical Imaging Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Background/Purpose: Patients with RA are prone to develop myocardial dysfunction, in which chronic inflammation is suggested to play an important role. We have previously shown…
Abstract Number: 2358 • 2017 ACR/ARHP Annual Meeting
Chest Pain and Angina Pectoris in Rheumatoid Arthritis: Frequency and Prediction of Cardiovascular Mortality
Jose Felix Restrepo¹, Inmaculada del Rincon¹, Carlos Lorenzo¹, Daniel Battafarano² and Agustin Escalante¹, ¹Internal Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ²Rheumatology, San Antonio Military Medical Center (SAMMC), San Antonio, TX
Background/Purpose: Despite increased cardiovascular (CV) risk in rheumatoid arthritis (RA), chest pain and angina have received little attention among RA patients. We examined the frequency…
Abstract Number: 2360 • 2017 ACR/ARHP Annual Meeting
A Correlation Study between Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis and Nailfold Videocapillaroscopy
Tania Adriana Luna-Zúñiga¹, Marco Ulises Martinez-Martinez², Enrique Cuevas-Orta¹, Georgina Martínez-Flores¹, Georgina Aguilera Barragán-Pickens¹, Angel Javier Pedro Martínez¹, Dolores Ramos-Bello³, Homero López-Ferretis¹, David Herrera Van Oostdam⁴ and Carlos Abud-Mendoza⁵, ¹Unidad Regional de Reumatologia y Osteoporosis Hospital Central "Dr. Ignacio Morones Prieto" y Facultad de Medicina de la UASLP, San Luis Potosí, Mexico, ²Unidad de Investigaciones Reumatológicas, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico, ³Reumatología, Unidad Regional de Reumatologia y Osteoporosis Hospital Central "Dr. Ignacio Morones Prieto" y Facultad de Medicina de la UASLP, San Luis Potosi, Mexico, ⁴Unidad de Investigaciones Reumatológicas, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ⁵Unidad de Investigaciones Reumatológicas y Osteoporosis, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico
Background/Purpose: The most common cause of mortality in RA patients is the cardiovascular disease (CVD), with almost twice the risk for CVD events. Nailfold videocapillaroscopy…

1
2
3
…
6
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].